Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115157) titled 'Propofol Optimizes the Rapid Antidepressant Effects of Esketamine in Treatment-Resistant Depression' on Dec. 23, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Changzhou NO.2 People's Hospital
Condition:
treatment-resistant depression
Intervention:
control group:Peripheral venous infusion of esketamine (with an anesthetic dose of 0.2mg/kg) for 40 minutes
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-01-01
Target Sample Size: control group:68;Optimized treatment group:68;
Countries of Recruitment:
China
To know more, visit https://www.ch...